false

m-content-container

/content/dam/corporate/images/research/drug-discovery-initiative/ddi-female-researcher-looking-through-a-microscope.jpg

37%

Partnerships

Advancing drug discovery projects

m-hero--style-1

800.534.2x.jpeg 1600w, 2000.1334.2x.jpeg 4000w, 1440.961.2x.jpeg 2880w, 1280.1280.jpeg 1280w, 220.147.2x.jpeg 440w, 440.294.2x.jpeg 880w

false

Addressing gaps in the pharmaceutical market requires rigorous academic research and technical innovation.

External partners can work with us to advance their projects toward preclinical development.

Our researchers provide technical expertise, consultation, and in-depth knowledge to support every stage in the drug discovery pipeline. 

_self

Get in touch

h2

Discuss partnership opportunities.

cmp-call-to-action--grey

How to work with us

Title : Academic collaboration

Description : Collaborate with an academic partner to solve a problem.

Link URL:

Icon: /content/dam/icons/approved-icons/like-minded-people.svg

Title : Engage our expertise

Description : Consult researchers to advance your project.

Link URL:

Icon: /content/dam/icons/approved-icons/laboratory-cell.svg

Title : Access our facilities

Description : Use world-class facilities with the assistance of our staff scientists.

Link URL:

Icon: /content/dam/icons/approved-icons/chemistry-set.svg

Find an expert

External partners can draw on our multidisciplinary network of more than 400 researchers to design and advance projects through custom drug discovery pipelines.

Our expertise spans fundamental research, to hit-to-lead, and drug formulation, and incorporates the latest techniques and technologies.

We approach projects from a translational biology perspective: establishing fit-for-purpose drug screening cascades that incorporate AI, 3D cell cultures and multiomics.

Our work is informed by input from biotech, pharmaceutical and healthcare representatives, foregrounding clinical and commercial relevance from the early stages.

Our study of disease mechanisms at a molecular level enables the discovery of novel and relevant drug targets.

We use proteomic and genomic techniques, AI and advance computer-assisted platforms to pinpoint druggable targets to tackle clinical and commercial needs focusing on:

  • CNS
  • Oncology 
  • Infectious diseases
  • Cardiovascular diseases

Computational and AI-based methodologies radically improve the efficiency of assay development and hit-to-lead activities.

Our researchers employ predictive platforms to capture accurate virtual models; improving screening, molecular docking and toxicity predictions.

We use a range of sophisticated methods to discover and validate hits. 

  • Fragment-based drug discovery
  • Cyclic peptide display screening
  • CRISPR screening
  • Screening in 2D and 3D cell cultures
  • Specialised assays

We design, synthesise and optimise novel compounds.

Our academic expertise spans organic and inorganic chemistry, protein expression, and the use of new chemical and biochemical technologies.

  • Small molecules 
  • Peptides 
  • PROTACs
  • Theranostics
  • Radiopharmaceuticals and chelators

Sophisticated non-animal models allow the efficacy and safety of new therapies to be tested with more accuracy.

Our researchers are developing new in vitro models that are highly reproducible and reliable for application in drug screening, imaging, data analysis and personlised medicine.

  • iPSCs
  • Organoids
  • Tumeroids
  • Microfluidic chips
  • Highthroughput platforms

Since the rapid development of the COVID-19 vaccine, the use of mRNA and biologics to treat a host of rare and common disease has flourished.

We’re formulating and stabilising nanoparticle and protein-based vaccines and therapeutics. 

  • Antibody-drug conjugates
  • mRNA therapeutics
  • Vaccines

To deliver accessible, patient-centric treatments, advancements in drug design must interlink with advancements in drug delivery.

Our pharmaceutical sciences experts are working on delivery methods that optimise how local and systemic diseases are treated.

  • Aerosols
  • Nanobodies

Stay in touch